Mallory bodies revisited

Journal of Hepatology

Volumn 32, Issue 4, 2000, Pages 689-702

  Denk, Helmut ^a,b   Stumptner, Cornelia ^a   Zatloukal, Kurt ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ASSOCIATION; LIVER CELL CARCINOMA; LIVER INJURY; MALLORY BODY; MORPHOLOGY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0034103895     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80233-0     Document Type: Review

References (123)

1. Mallory FB. Cirrhosis of the liver: five different lesions from which it may arise. Bull Johns Hopkins Hosp. 22:1911;69-75.
2. Denk H, Franke WW, Kerjaschki D, Eckersdorfer R. Mallory bodies in experimental animals and man. Int Rev Exp Pathol. 20:1979;77-121.
3. Jensen K, Gluud C. The Mallory body: morphological, clinical and experimental studies. (part 1 of a literature survey) Hepatology. 20:1994;1061-1077.
4. Jensen K, Gluud C. The Mallory body: theories on development and pathological significance. (part 2 of a literature survey) Hepatology. 20:1994;1330-1342.
5. Denk H, Lackinger E. Cytoskeleton in liver diseases. Semin Liver Dis. 6:1986;199-211.
6. French SW, Nash J, Shitabata P, Kachi K, Hara C, Chedid A, et al. Pathology of alcoholic liver disease. Semin Liver Dis. 13:1993;154-169.
7. Hall P. Pathological spectrum of alcoholic liver disease. Hall P. Alcoholic Liver Disease. Pathology and Pathogenesis. 1995;41-68 Edward Arnold, London, Boston, Melbourne, Auckland.
8. Ishak KG, Zimmerman HJ, Ray MB. Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. 15:1991;45-66 Clin Exp Res, Alcoholism.
9. Zimmerman HJ, Ishak KG. Non-alcoholic steatohepatitis and other forms of pseudo-alcoholic liver disease. Hall P. Alcoholic Liver Disease. Pathology and Pathogenesis. 1995;175-198 Edward Arnold, London, Boston, Melbourne, Auckland.
10. James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol. 20:1998;495-501.
11. Baptista A, Bianchi L, DeGroote J, Desmet VJ, Gedigk P, Korb G, et al. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet. i:1981;707-711.
12. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagnostic Pathol. 15:1998;246-258.
13. Franke WW, Denk H, Schmid E, Osborn M, Weber K. Ultrastructural, biochemical and immunologic characterization of Mallory bodies in livers of griseofulvin-treated mice. Fimbriated rods of filaments containing prekeratin-like polypeptides. Lab Invest. 40:1979;207-220.
14. Katsuma Y, Swierenga SHH, Khettry U, Marceau N, French SW. Changes in the cytokeratin intermediate filament cytoskeleton associated with Mallory body formation in mouse and human liver. Hepatology. 7:1987;1215-1223.
15. Bosron WF, Ehrig T, Li TK. Genetic factors in alcohol metabolism and alcoholism. Semin Liver Dis. 13:1993;126-135.
16. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology. 26:1997;143-146.
17. Lindros KO. Alcoholic liver disease: pathobiological aspects. J Hepatol. 23:(Suppl):1995;7-15.
18. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Non alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 55:1980;434-438.
19. Denk H, Gschnait F, Wolff K. Hepatocellular hyalin (Mallory bodies) in long term griseofulvin-treated mice: a new experimental model for the study of hyalin formation. Lab Invest. 32:1975;773-776.
20. Tsunoo C, Harwood TR, Arak S, Yokoo H. Cytoskeletal alterations leading to Mallory body formation in livers of mice fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine. J Hepatol. 5:1987;85-97.
21. Yokoo H, Minick OT, Batti F, Kent G. Morphologic variants of alcoholic hyalin. Am J Pathol. 69:1972;25-40.
22. Lieber CS, DeCarli LM, Sorrell MF. Experimental methods of ethanol administration. Hepatology. 10:1989;501-510.
23. French SW, Morimoto M, Tsukamoto H. Animal models of alcohol-associated liver injury. Hall P. Alcoholic Liver Disease. Pathology and pathogenesis. 1995;279-296 Edward Arnold, London, Boston, Melbourne, Auckland.
24. Tsukamoto H, French SW, Benson N, Delgado G, Rao GA, Larkin EC, et al. Severe and progressive steatosis and focal necrosis in rat liver induced by continuous intragastric infusion of ethanol and low fat diet. Hepatology. 5:1985;224-232.
25. Tsukamoto H, Gad K, French SW. Insights into the pathogenesis of alcoholic liver necrosis and fibrosis: status report. Hepatology. 12:1990;599-608.
26. Tsukamoto H, Horne W, Kamimura S, Niemelä O, Parkkila S, Yiä-Herttuala S, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 96:1995;620-630.
27. Tsukamoto H, Cheng S, Blander WS. Effects of dietary polyunsaturated fat on ethanol-induced Ito cell activation. Am J Physiol. 270:(Gastrointest Liver Physiol 33):1996;G581-G586.
28. Denk H, Eckerstorfer R, Gschnait F, Konrad K, Wolff. K Experimental induction of hepatocellular hyalin (Mallory bodies) in mice by griseofulvin treatment. I. Light microscopic observations. Lab Invest. 35:1976;377-382.
29. Ortiz de Montellano PR, Beilan HS, Kunze KL. N-alkylprotoporphyrin IX formation in 3,5-dicarbethoxy-1,4-dihydrocollidine-treated rats. Transfer of the alkyl group from the substrate to the porphyrin. J Biol Chem. 256:1981;6708-6713.
30. Knasmüller S, Parzefall W, Helma C, Kassie F, Ecker S, Schulte-Hermann R. Toxic effects of griseofulvin: disease models, mechanisms, and risk assessment. Crit Rev Toxicol. 27:1997;495-537.
31. Denk H, Franke WW, Eckerstorfer R, Schmid E, Kerjaschki D. Formation and involution of Mallory bodies (alcoholic hyalin) in murine and human liver revealed by immunofluorescence microscopy with antibodies to prekeratin. Proc Natl Acad Sci USA. 76:1979;4112-4116.
32. Denk H, Franke WW, Dragosics B, Zeiler I. Pathology of cytoskeleton of liver cells: demonstration of Mallory bodies (alcoholic hyalin) in murine and human hepatocytes by immunofluorescence microscopy using antibodies to cytokeratin polypeptides from hepatocytes. Hepatology. 1:1981;9-20.
33. Denk H, Krepler R, Lackinger E, Artlieb U, Franke WW. Immunological and biochemical characterization of the keratinrelated component of Mallory bodies: a pathological pattern of hepatocytic cytokeratins. Liver. 2:1982;165-175.
34. Okanoue T, Ohta M, Ou O, Kachi K, Kagawa K, Yuki T, et al. Relationship of Mallory bodies to intermediate filaments in hepatocytes. A scanning electron microscopy study. Lab Invest. 53:1985;534-540.
35. Hazan R, Denk H, Franke WW, Lackinger E, Schiller DL. Change of cytokeratin organization during development of Mallory bodies as revealed by a monoclonal antibody. Lab Invest. 54:1986;543-553.
36. Zatloukal K, Boeck G, Rainer I, Denk H, Weber K. High molecular weight components are main constituents of Mallory bodies isolated with a fluorescence activated cell sorter. Lab Invest. 64:1991;200-206.
37. Zatloukal K, Spurej G, Rainer I, Lackinger E, Denk H. Fate of Mallory body-containing hepatocytes: disappearance of Mallory bodies and restoration of the hepatocytic intermediate filament cytoskeleton after drug withdrawal in the griseofulvintreated mouse. Hepatology. 11:1990;652-661.
38. Lowe J, Blanchard A, Morell K, Lennox G, Reynolds L, Billet M, et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibers in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol. 155:1988;9-15.
39. Ohta M, Marceau N, Perry G, Manetto V, Gambetti P, Autilio-Gambetti L, et al. Ubiquitin is present on the cytokeratin intermediate filaments and Mallory bodies of hepatocytes. Lab Invest. 59:1988;848-856.
40. Zatloukal K, Denk H, Spurej G, Lackinger E, Preisegger KH, Franke WW. High molecular weight component of Mallory bodies detected by a monoclonal antibody. Lab Invest. 62:1990;427-434.
41. Preisegger KH, Zatloukal K, Spurej G, Riegelnegg D, Denk H. Common epitopes of human and murine Mallory bodies and Lewy bodies as revealed by a neurofilament antibody. Lab Invest. 66:1992;193-199.
42. M120-1 in vitro. Hepatology. 24:1996;129A.
43. Nukina N, Kosik KS, Selkoe DJ. Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein. Proc Natl Acad Sci USA. 84:1987;3415-3419.
44. Lichtenberg-Kraag B, Mandelkow EM, Biernat J, Steiner B, Schröter C, Gustke N, et al. Phosphorylation - dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau. Proc Natl Acad Sci USA. 89:1992;5384-5388.
45. Mandelkow EM, Mandelkow E. Tau as a marker for Alzheimer's disease. Trends Biol Sci. 18:1993;480-483.
46. Westendorf JM, Rao PN, Gerace L. Cloning of cDNAs for Mphase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope. Proc Natl Acad Sci USA. 91:1994;714-718.
47. Vincent I, Rosado M, Davies P. Mitotic mechanisms in Alzheimer's disease. J Cell Biol. 132:1996;413-425.
48. Kondratick CM, Vandre DD. Alzheimer's disease neurofibrillary tangles contain mitosis-specific phosphoepitopes. J Neurochem. 67:1996;2405-2416.
49. Stumptner C, Heid H, Fuchsbichler A, Hauser H, Mischinger HJ, Zatloukal K, et al. Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent. Am J Pathol. 154:1999;1701-1710.
50. lck belongs to a new class of ubiquitin-binding proteins. J Biol Chem. 271:1996;20235-20237.
51. lck SH2 domain. Proc Natl Acad Sci USA. 93:1996;5991-5995.
52. Shin J. P62 and the sequestosome, a novel mechanism for protein metabolism. Arch Pharm. 21:1998;629-633.
53. Vadlamudi RK, Shin J. Genomic structure and promoter analysis of the p62 gene encoding a non-proteasomal multi-ubiquitin chain binding protein. FEBS Lett. 435:1998;138-142.
54. Lee YH, Ko J, Joung I, Kim JH, Shin J. Immediate early response of the p62 gene encoding a non-proteasomal multiubiquitin chain binding protein. FEBS Lett. 438:1998;297-300.
55. Lowe J, Mayer RJ, Landon M. Ubiquitin in neurodegenerative diseases. Brain Pathol. 3:1993;55-65.
56. Bergmann M. Motor neuron disease/amyotrophic lateral sclerosis - lessons from ubiquitin. Path Res Pract. 189:1993;902-912.
57. Julien JP. Neurofilaments and motor neuron disease. Trends Cell Biol. 7:1997;243-248.
58. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 79:1994;13-21.
59. Weissman A.M. Regulating protein degradation by ubiquitination. Immunol Today. 18:1997;189-198.
60. Lowe J, McDermott H, Pike I, Spendlove I, Landon M, Mayer RJ. αB crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human disease. J Pathol. 166:1992;61-68.
61. Yuan QX, Marceau N, French BA, Fu P, French SW. Heat shock in vivo induces Mallory body formation in drug primed mouse liver. Exp Mol Pathol. 63:1995;63-76.
62. Hartl FU. Molecular chaperones in cellular protein folding. Nature. 381:1996;571-580.
63. Rassow J, Ahsen O, Boiner U, Pfanner N. Molecular chaperones: towards a characterization of the heat-shock protein 70 family. Trend Cell Biol. 7:1997;129-133.
64. Fataccioli V, Andrand E, Gentil M, French SW, Rouach H. Effects of chronic ethanol administration on rat liver proteasome activities: relationship with oxidative stress. Hepatology. 29:1999;14-20.
65. Cadrin M, Marceau N, French SW. Cytokeratin of apparent high molecular weight in livers from griseofulvin-fed mice. J Hepatol. 14:1992;226-231.
66. Zatloukal K, Fesus L, Denk H, Tarcsa E, Spurej G, Böck G. High amount of ε-(γ-glutamyl) lysine cross-links in Mallory bodies. Lab Invest. 66:1992;774-777.
67. Cadrin M, French SW, Wong TT. Alteration in molecular structure of cytoskeleton proteins in griseofulvin-treated mouse liver: a pressure tuning infrared spectroscopy study. Exp Mol Pathol. 55:1991;170-179.
68. Li CJ, Nanji AA, Siakotos AN, Lin RC. Acetaldehyde-modified and 4-hydroxynonenal-modified proteins in the livers of rats with alcoholic liver disease. Hepatology. 26:1997;650-657.
69. Lieber CS. Biochemical factors in alcoholic liver disease. Semin Liver Dis. 13:1993;136-153.
70. Tuma DJ, Sorrell MF. The role of acetaldehyde adducts in liver injury. Hall P. Alcoholic Liver Disease. 1995;89-99 Edward Arnold, Pathology and Pathogenesis, London, Boston, Melbourne, Auckland.
71. Breathnach SM. The cutaneous amyloidoses. Pathogenesis and therapy. Arch Dermatol. 121:1985;470-475.
72. Röcken C, Schwotzer EB, Linke RP, Saeger W. The classification of amyloid deposits in clinicopathological practice. Histopathology. 29:1996;325-335.
73. Ku NO, Liao J, Chon CF, Omary MB. Implications of intermediate filament protein phosphorylation. Cancer Metastasis Rev. 15:1996;429-444.
74. Omary MB, Ku NO. Intermediate filament proteins of the liver: emerging disease association and function. Hepatology. 25:1997;1043-1048.
75. Stumptner C, Omary MB, Fickert P, Denk H, Zatloukal K. Hepatocyte cytokeratins are hyperphosphorylated at multiple sites in human alcoholic hepatitis and in a Mallory body mouse model. Am J Pathol, in press.
76. Salmhofer H, Rainer I, Zatloukal K, Denk H. Posttranslational events involved in griseofulvin-induced keratin cytoskeleton alterations. Hepatology. 20:1994;731-740.
77. Cadrin M, McFarlane, Anderson N, Aasheim LH, Kawahara H, Franks DJ, et al. Modifications in cytokeratin and actin in cultured liver cells derived from griseofulvin-fed mice. Lab Invest. 72:1995;453-460.
78. Klassen LW, Tuma D, Sorrell MF. Immune mechanisms in alcohol-induced liver disease. Hepatology. 22:1995;355-357.
79. Denk H, Lackinger E, Cowin P, Franke WW. Maintenance of desmosomes in mouse hepatocytes after drug-induced rearrangement of cytokeratin filament material. Exp Cell Res. 161:1985;161-171.
80. Denk H, Franke WW. Rearrangement of the hepatocyte cytoskeleton after toxic damage: involution, dispersal and peripheral accumulation of Mallory body material after drug withdrawal. Eur J Cell Biol. 23:1981;241-249.
81. Denk H, Eckerstorfer R. Colchicine-induced Mallory body formation in the mouse. Lab Invest. 36:1977;563-565.
82. Zatloukal K, Stumptner C, Fuchsbichler A, Lehner M, Denk H. Induction of Mallory bodies reflects a toxic memory response and is linked to overexpression of cytokeratin mRNA in hepatocytes. Hepatology. 24:1996;601A.
83. Yuan QX, Nagao Y, Gaal K, Hu B, French SW. Mechanism of Mallory body formation induced by okadaic acid in drugprimed mice. Exp Mol Pathol. 65:1998;87-103.
84. Yuan Q, French BA, French SW. Tautomycin induces extensive Mallory body formation in drug primed mouse livers. Hepatology. 28:1998;256A.
85. Zhang-Gouillon ZQ, Yuan QX, Hu B, Marceau B, French BA, Gaal K, et al. Mallory body formation by ethanol feeding in drug-primed mice. Hepatology. 27:1998;116-122.
86. Yuan QX, Marceau N, French BA, Fu P, French SW. Mallory body induction in drug-primed mouse liver. Hepatology. 24:1996;603-612.
87. Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology. 20:1994;453-460.
88. Bjarnson I, Peters TJ, Wise RJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet. i:1984;179-182.
89. Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute ethanol excess. J Hepatol. 4:1987;8-14.
90. Caraceni P, Ryu HS, Subbotin V, De Maria N, Colantoni A, Roberts L, et al. Rat hepatocytes isolated from alcohol-induced fatty liver have an increased sensitivity to anoxic injury. Hepatology. 25:1997;934-949.
91. Deaciuc IV. Alcohol and cytokine networks. Alcohol. 14:1997;421-430.
92. Dilger K, Metzler J, Bode JC, Klotz V. CYP 2E1 activity in patients with alcoholic liver disease. J Hepatol. 27:1997;1009-1014.
93. Ganey PE, Bailie MB, VanCise S, Colligan ME, Madhukar BV, Robinson JP, et al. Activated neutrophils from rat injured isolated hepatocytes. Lab Invest. 70:1994;53-60.
94. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology. 26:1997;1530-1537.
95. Ingelman-Sundberg M, Johansson I. Mechanisms of hydroxyl radical formation and ethanol oxidation by ethanol-inducible and other forms of rabbit liver microsomal cytochrome P-450. J Biol Chem. 259:1984;6447-6458.
96. Jaeschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol. 260:1991;G355-G362.
97. Kukielka E, Dicker E, Cederbaum AI. Increased production of reactive oxygen species by rat liver mitochondria after chronic ethanol treatment. Arch Biochem Biophys. 309:1994;377-386.
98. Lauterburg BH, DeQuay B. Radicals and oxidants in ethanol induced liver injury. Moslen MT, Smith CV. Free radical mechanisms of tissue injury. 1992;33-43 CRC Press, London, Tokyo, Boca Raton, Ann Arbor.
99. Nanji AA, Khettry U, Sadrzadeh SMH, Yamanaka T. Severity of liver injury in experimental alcoholic liver disease. Correlation with plasma endotoxin, prostaglandin E2, leukotriene B4, and thromboxane B2. Am J Pathol. 142:1993;167-173.
100. Rouach H, Fataccioli V, Gentil M, French SW, Morimoto M, Nordmann R. Effect of chronic ethanol feeding on lipid peroxidation and protein oxidation in relation to liver pathology. Hepatology. 25:1997;351-355.
101. Wieland P, Lauterburg BA. Oxidation of mitochondrial proteins and DNA following administration of ethanol. Biochem Biophys Res Comm. 213:1995;815-819.
102. Hoek JB. Endotoxin and alcoholic liver disease: tolerance andsusceptibility. (editorial) Hepatology. 29:1999;1602-1604.
103. Bailey SM, Cunningham CC. Acute and chronic ethanol increase reactive oxygen species generation and decrease viability in fresh, isolated rat hepatocytes. Hepatology. 28:1998;1318-1326.
104. Castillo T, Koop DR, Kamimura S, Triadafilopoulos G, Tsukamoto H. Role of cytochrome P-450 2E1 in ethanol-, carbon tetrachloride- and iron-dependent microsomal lipid peroxidation. Hepatology. 16:1992;992-996.
105. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with non alcoholic steatohepatitis. Hepatology. 27:1998;128-133.
106. Rouach H, Fataccioli V, Gentil M, French SW, Marimoto M, Nordmann R. Effect of chronic ethanol feeding on lipid peroxidation and protein oxidation in relation to liver pathology. Hepatology. 25:1997;351-355.
107. Johnson FB, Sinclair DA, Guarente L. Molecular biology of aging. Cell. 96:1999;291-302.
108. Ando Y, Suhr O, El-Salhy M. Oxidative stress and amyloidosis. Histol Histopathol. 13:1998;845-850.
109. Hutter H, Zatloukal K, Winter G, Stumptner C, Denk H. Disturbance of keratin homeostasis in griseofulvin-intoxicated mouse liver. Lab Invest. 69:1993;576-582.
110. Kachi K, Cadrin M, French SW. Synthesis of Mallory body, intermediate filament, and microfilament proteins in liver cell primary cultures. Lab Invest. 68:1993;71-81.
111. Skalli O, Chou YH, Goldman RD. Intermediate filaments: not so tough after all. Trends Cell Biol. 2:1992;308-312.
112. Baribault H, Price H, Miyai K, Oshima RG. Mid-gestational lethality in mice lacking keratin 8. Genes Dev. 7:1993;1191-1202.
113. Baribault H, Penner J, Iozzo RV, Wilson-Heiner M. Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice. Genes Dev. 8:1994;2964-2974.
114. Zatloukal K, Stumptner C, Lechner M, Fuchsbichler A, Eshkind LG, Baribault H, et al. Cytokeratin protects hepatocytes from intoxication: a possible new function of intermediate filaments revelaed by cytokeratin 8 knock-out mice. Hepatology. 26:1997;182A.
115. Franke WW, Denk H, Kalt R, Schmid E. Biochemical and immunological identification of cytokeratin proteins present in hepatocytes of mammalian liver tissue. Exp Cell Res. 131:1981;299-318.
116. Moll R, Franke WW, Schiller D, Geiger B, Krepler R. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell. 31:1982;11-24.
117. Magin TM, Schröder R, Leitgeb S, Wanninger F, Zatloukal K, Grund C, et al. Lessons from keratin 18 knockout mice; formation of novel keratin filaments, secondary loss of keratin 7 and accumulation of liver specific keratin 8-positive aggregates. J Cell Biol. 140:1998;1441-1451.
118. Baumann PA, Dalton WS, Anderson JM, Cress AE. Expression of cytokeratin confers multiple drug resistance. Proc Natl Acad Sci USA. 91:1994;5311-5314.
119. Ku NO, Michie SA, Soetikno RM, Resurreccion EZ, Broome RL, Oshima RG, et al. Susceptibility to hepatotoxicity in transgenic mice that express a dominant-negative human keratin 18 mutant. J Clin Invest. 98:1996;1034-1046.
120. Ku NO, Wright TL, Terrault NA, Gish R, Omary MB. Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest. 99:1997;19-23.
121. Taubes G. Misfolding the way to disease. Science. 271:1996;1493-1496.
122. Johnston JA, Ward CL, Kapito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol. 143:1998;1883-1898.
123. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8:1998;397-403.